TPTX Projected Dividend Yield
Turning Point Therapeutics Inc ( NASDAQ : TPTX )Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing therapies that target genetic drivers of cancer. Co.'s main drug candidate, repotrectinib, is being evaluated for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and patients with NTRK+ advanced solid tumors. Elzovantinib, Co.'s MET/SRC/CSF1R inhibitor, is being evaluated in its ongoing Phase 1 SHIELD-1 clinical trial, in patients with advanced solid tumors harboring genetic alterations in MET. Co.'s clinical trial of its RET inhibitor, TPX-0046 in patients with advanced solid tumors is ongoing. Co.'s fourth drug candidate, TPX-0131, is an ALK inhibitor. 20 YEAR PERFORMANCE RESULTS |
TPTX Dividend History Detail TPTX Dividend News TPTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |